Primary trigeminal neuralgia refers to paroxysmal pain in the sensory distribution area of the trigeminal nerve without a clear cause, and is a common and frequent clinical disease. Its incidence is recently reported to be about 8/100,000, and the age of 50-60 is the high incidence age. According to the clinical symptoms, primary trigeminal neuralgia can be divided into typical and atypical. The former has a short duration of pain, which is pinprick-like or electric shock-like, and can be spontaneous or caused by slight stimulation of the “trigger point”; the latter has a long duration and can cause facial numbness. It causes great pain to patients and seriously affects their work and life. At present, there are more methods to treat trigeminal neuralgia, and there is no uniform standard for the selection of treatment indications, and the treatment effect also varies greatly. The classification by drug and surgical treatment is as follows: drug treatment: oral antiepileptic drugs carbamazepine, phenytoin sodium, sodium valproate, etc. Most scholars believe that oral carbamazepine monotherapy is preferred, and if pain relief is not obvious, the latter can be combined with oral administration. In foreign countries, lidocaine nasal spray has been applied to treat patients with pain in the 2nd branch of the trigeminal nerve, and the mechanism is to block the pterygopalatine ganglion. Surgical treatment: 1. Surgery of the peripheral branch of the trigeminal nerve: peripheral neurotomy, anhydrous alcohol injection and cryotherapy. The former is prone to sensory loss and transient or permanent facial paralysis; the latter two have a higher safety profile, but also have a higher recurrence rate. 2, trigeminal nerve hemimelia surgery: percutaneous puncture radiofrequency thermocoagulation. The unmyelinated fine fibers (Aδ and C fibers) that conduct nociception in the nerve are the first to degenerate after heating, while the myelinated thick fibers (Aα and Aβ fibers) that conduct tactile sensation can tolerate higher temperatures. Transcutaneous percutaneous radiofrequency thermocoagulation is used to selectively destroy nociceptive fibers by temperature-controlled heating to achieve pain relief. This method is less invasive and has fewer complications, and is suitable for patients of advanced age or with impairment of vital organ function. The key to this procedure is accurate puncture positioning. X-ray fluoroscopy and CT-assisted positioning can greatly improve the success rate of puncture and reduce complications. 3.Posterior cranial fossa surgery: trigeminal nerve microvascular decompression. After this operation is opened, the compression of the trigeminal nerve in the brainstem segment by microvascular vessels is released, and the integrity of the trigeminal nerve is maintained. The healing rate is high and complications are few, but the trauma is relatively large compared to RF. Since minimally invasive radiofrequency ablation was carried out in 2006, the pain department has successfully cured 281 patients with trigeminal neuralgia, which has relieved the pain of the majority of patients. At the same time, minimally invasive radiofrequency ablation has also been applied to the treatment of lumbar disc herniation and cervical spondylosis, which has also achieved very good results. Practice has proved that minimally invasive radiofrequency ablation is a good treatment for trigeminal neuralgia with small trauma, high safety, short hospitalization time and low cost.